Adjuvant Olaparib in BRCA-Mutated Breast Cancer: The OlympiA Trial | OncLive
Adjuvant Olaparib in BRCA-Mutated Breast Cancer: The OlympiA Trial | OncLive
May 18, 2022
onclive.com
Phase III Olympia Trial: Adjuvant Olaparib Prolongs Survival for Certain Patients With Early Breast Cancer
Phase III Olympia Trial: Adjuvant Olaparib Prolongs Survival for Certain Patients With Early Breast Cancer
134 viewsMay 13, 2022
vumedi.com
Olaparib plus pembrolizumab shows promising results in BRCA mutation cancers
2:58
Olaparib plus pembrolizumab shows promising results in BRCA mutation cancers
34 views8 months ago
YouTubeecancer
Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer
Olaparib Beneficial for BRCA-Mutated HER2-Negative Breast Cancer
Jun 11, 2021
medscape.com
OlympiAD: Olaparib Captures Gold for BRCA Breast Cancer
OlympiAD: Olaparib Captures Gold for BRCA Breast Cancer
Jun 12, 2017
medscape.com
The Mechanism of Action of Olaparib | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
The Mechanism of Action of Olaparib | Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
Jul 30, 2013
targetedonc.com
💊 Cambridge research has led to a life-saving cancer drug. In 1999, Professor Sir Steve Jackson set up a team of scientists that created olaparib, a new class of cancer drug, which has now been used to treat over 140,000 patients globally and changed the outlook for people with breast, ovarian, prostate and pancreatic cancers. Find out how we're #ChangingTheStoryOfCancer 👉 https://www.cam.ac.uk/stories/olaparib-cancer-drug-steve-jackson?utm_medium=social&utm_source=facebook #CambridgeUniversit
1:05
💊 Cambridge research has led to a life-saving cancer drug. In 1999, Professor Sir Steve Jackson set up a team of scientists that created olaparib, a new class of cancer drug, which has now been used to treat over 140,000 patients globally and changed the outlook for people with breast, ovarian, prostate and pancreatic cancers. Find out how we're #ChangingTheStoryOfCancer 👉 https://www.cam.ac.uk/stories/olaparib-cancer-drug-steve-jackson?utm_medium=social&utm_source=facebook #CambridgeUniversit
1.3K viewsJul 17, 2024
FacebookUniversity of Cambridge
Olaparib for Germline BRCA1/2 Metastatic Pancreatic Adenocarcinoma: Second-Line Maintenance Therapy
Feb 17, 2021
medscape.com
4:20
OlympiA Study Demonstrates the Efficacy of Olaparib in the Treatment of Early Breast Cancer
222 viewsJan 23, 2025
YouTubeDocWire
4:41
Exploring the role of olaparib and treatment intensification in high-risk breast cancer
177 viewsOct 24, 2024
YouTubeVJOncology
3:26
New Treatment on the Horizon | PARP inhibitor - olaparib
2.6K viewsJul 27, 2021
YouTubeBreast Cancer Now
SOLO1: 7-Year Follow-up Highlights the Value of Maintenance Olaparib
Dec 12, 2022
medscape.com
SGO 2022 Update on Maintenance Olaparib Rechallenge in Patients With Ovarian Carcinoma: Results From the OReO/ENGOT Ov-38 Trial
76 viewsMar 24, 2022
vumedi.com
2:48
Rationale for Olaparib in Advanced Ovarian Cancer
119 viewsJun 22, 2018
YouTubeTargeted Oncology
6:48
Olaparib Shows 'Unbelievable' Response Rate in MBC With PALB2 or BRCA Mutations
Jul 8, 2024
medpagetoday.com
1:31
Melanie was diagnosed with ovarian cancer in 2018. She's one of over 140,000 people to receive the drug olaparib, developed by Professor Sir Steve Jackson. Find out how a chance discovery led to a drug that's #ChangingTheStoryOfCancer 👉 https://www.cam.ac.uk/stories/olaparib-cancer-drug-steve-jackson #CambridgeUniversity #UniversityOfCambridge #Cambridge #Cancer #CancerDiagnosis #OvarianCancer | University of Cambridge
1.6K viewsJul 19, 2024
FacebookUniversity of Cambridge
0:22
Olympia Trial: Olaparib Improves Breast Cancer Survival! Key Results
26 views5 months ago
YouTubei3 Health
2:46
Dr. Brufsky on the FDA Approval of Olaparib in BRCA+ Breast Cancer
215 viewsJan 12, 2018
YouTubeOncLive
4:03
19 Medicine of the week: Olaparib
592 viewsJan 29, 2025
YouTubeLékařská fakulta Masarykovy univerzity
0:49
Dr. Tung Discusses the Role of Olaparib in Breast Cancer
297 viewsMar 30, 2018
YouTubeOncLive
Dr. Agarwal on the FDA Approval of Olaparib in HRR-Mutant mCRPC | OncLive
May 19, 2020
onclive.com
New Hope For Later Stage Prostate Cancer Patients: The PARP Inhibitor Olaparib Approved By The FDA
May 21, 2020
survivornet.com
2:39
My BRCA Pill Journey: Olaparib and Lynparza Insights
2.9K views7 months ago
TikTokdanakroppcancer
PARP Inhibitor Olaparib Delivers Strong Results in Selected Prostate Cancer Cases
May 5, 2025
medscape.com
11:49
BRCA & PARP Inhibitors: Targeted Chemotherapy | #MarkScholzMD #AlexScholz @PCRI
5.8K viewsJun 1, 2023
YouTubeProstate Cancer Research Institute
2:26
The Promise of Olaparib for the Treatment of HER2-Negative Breast Cancer
786 viewsJun 27, 2017
YouTubeTargeted Oncology
0:36
BRCA1 & BRCA2 Mutations: PARP Inhibitors
4.1K views10 months ago
YouTubeYerbba – Breast Cancer
4:09
What are PARP Inhibitors for Breast Cancer? | Lynparza (olaparib) Explained
2.4K views11 months ago
YouTubeYerbba – Breast Cancer
Astrazeneca Pharma India Surrenders Marketing Authorisation For Olaparib Tablets
Apr 14, 2025
marketscreener.com
4:13
Replying to @Lydiacolors Ever wonder why some women with BRCA1 or BRCA2 mutations are prescribed Lynparza (olaparib) instead of Tamoxifen? Both are used in breast cancer — but they work in completely different ways. 💊 👉 Tamoxifen is a hormone therapy that blocks estrogen — stopping hormone-positive breast cancers from getting the “fuel” they need to grow. 👉 Lynparza, on the other hand, is a targeted therapy for people with BRCA1/2 mutations. It works by blocking a repair protein called PARP,
2.1K views7 months ago
TikTokjasvir.kaur.pharmd
See more